After moving 0.7% during today's evening session, Regeneron Pharmaceuticals is now trading at a price of $830.69 per share. On average, analysts give it a target price of $898.86.
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide.
Potential Regeneron Pharmaceuticals Investors Should Analyze the Following:
Regeneron Pharmaceuticals has moved 15.0% over the last year.
The company has a price to earnings growth (PEG) ratio of 4.2. A number between 0 and 1 could mean that the market is undervaluing Regeneron Pharmaceuticals's estimated growth potential
Its Price to Book (P/B) ratio is 3.68
Understanding Regeneron Pharmaceuticals's Operating Margins
|Date Reported||Total Revenue ($ k)||Operating Expenses ($ k)||Operating Margins (%)||YoY Growth (%)|
Regeneron Pharmaceuticals's operating margins have averaged 43.0% over the last 6 years, which is significantly higher than the Pharmaceutical industry average of 12.02%. The firm's margins exhibit a relatively stable growth trend of 2.7%.